Axiom Advisory LLC Buys 621 Shares of Danaher Co. (NYSE:DHR)

Axiom Advisory LLC lifted its position in Danaher Co. (NYSE:DHR) by 3.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 19,264 shares of the conglomerate’s stock after purchasing an additional 621 shares during the quarter. Axiom Advisory LLC’s holdings in Danaher were worth $5,098,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in DHR. Tsfg LLC boosted its holdings in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new stake in shares of Danaher in the second quarter valued at $25,000. nVerses Capital LLC bought a new position in shares of Danaher in the second quarter valued at about $25,000. Redmont Wealth Advisors LLC bought a new position in shares of Danaher in the first quarter valued at about $30,000. Finally, Richardson Financial Services Inc. acquired a new position in Danaher during the 4th quarter worth about $42,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Price Performance

Shares of NYSE:DHR opened at $268.79 on Tuesday. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The company has a 50-day moving average price of $271.07 and a two-hundred day moving average price of $258.64. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $199.09 billion, a PE ratio of 45.56, a P/E/G ratio of 4.55 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the previous year, the firm posted $2.05 EPS. The firm’s revenue was down 2.9% compared to the same quarter last year. Equities analysts forecast that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Leerink Partners boosted their target price on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Bank of America upped their target price on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Stephens initiated coverage on shares of Danaher in a research report on Tuesday, October 1st. They set an “overweight” rating and a $315.00 price target for the company. Stifel Nicolaus increased their price objective on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Finally, TD Cowen lifted their target price on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $282.12.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.